First Trust Nasdaq Pharmaceuticals ETF Rating → Bigger Than NVIDIA? (From Behind the Markets) (Ad) Free FTXH Stock Alerts $26.99 -0.06 (-0.22%) (As of 06/17/2024 ET) Add Compare Share Share RatingsStock AnalysisChartDividendHoldingsOptions ChainOwnershipRatingsShort InterestTrendsStock AnalysisChartDividendHoldingsOptions ChainOwnershipRatingsShort InterestTrends First Trust Nasdaq Pharmaceuticals ETF Aggregate Rating and Price Target (2024)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.FTXH Aggregate RatingModerate Buy2.59Holdings in FTXH have an aggregate rating of Moderate Buy based on 668 analyst ratings issued in the past year covering 50 companies (99.9% of the portfolio).FTXH Aggregate Price Target$32.4620.25% UpsideHigh Prediction$41.06Average Prediction$32.46Low Prediction$24.46Holdings in FTXH have an aggregate price target of $32.46 and a range of $24.46 to $41.06 covering 50 companies (99.9% of the portfolio).FTXH Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy7 Buy rating(s)Moderate Buy34 Moderate Buy rating(s)Hold8 Hold rating(s)Reduce0 Reduce rating(s)Sell1 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by First Trust Nasdaq Pharmaceuticals ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 50 FTXH Holdings Export to ExcelWeightIn ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings7.95%PFEPfizer$26.99-2.0%5 of 5 stars2.40$35.86 32.9%15Analyst Forecast7.52%MRKMerck & Co., Inc.$127.52-1.5%4 of 5 stars2.69$133.00 4.3%13Options Volume7.02%ABBVAbbVie$169.70+0.7%5 of 5 stars2.86$178.21 5.0%146.65%JNJJohnson & Johnson$145.97+0.3%5 of 5 stars2.38$174.07 19.3%13Analyst ForecastShort Interest ↑5.90%BMYBristol-Myers Squibb$40.97-0.6%5 of 5 stars2.11$60.00 46.4%19Analyst Downgrade4.23%VRTXVertex Pharmaceuticals$473.69-1.5%4 of 5 stars2.52$443.55 -6.4%25Analyst Upgrade4.09%AMGNAmgen$303.28+1.6%5 of 5 stars2.52$305.85 0.8%21Analyst ForecastShort Interest ↓4.07%UTHRUnited Therapeutics$297.06+3.1%4 of 5 stars2.90$312.22 5.1%10Insider Selling4.07%LLYEli Lilly and Company$885.01+0.7%5 of 5 stars2.84$787.53 -11.0%19Analyst ForecastInsider Selling3.92%BIIBBiogen$226.46-2.3%5 of 5 stars2.65$286.50 26.5%26Short Interest ↓3.80%REGNRegeneron Pharmaceuticals$1,045.37+0.9%4 of 5 stars2.77$998.09 -4.5%22Analyst ForecastInsider Selling3.27%ZTSZoetis$170.87+0.2%5 of 5 stars3.00$211.75 23.9%7Positive News3.25%GILDGilead Sciences$64.27-1.2%5 of 5 stars2.35$83.69 30.2%17Ex-DividendAnalyst ForecastOptions Volume3.23%CAHCardinal Health$100.94+0.7%4 of 5 stars2.50$109.67 8.6%12Short Interest ↓Positive News3.09%VTRSViatris$10.11-0.6%1 of 5 stars1.33$11.00 8.8%3Insider Selling3.00%OGNOrganon & Co.$20.34-0.3%5 of 5 stars2.50$22.60 11.1%4Positive News2.88%JAZZJazz Pharmaceuticals$114.53+1.4%5 of 5 stars2.86$190.92 66.7%14Positive News1.91%CRLCharles River Laboratories International$208.41-0.5%4 of 5 stars2.62$256.38 23.0%13Analyst DowngradeShort Interest ↑1.63%HALOHalozyme Therapeutics$49.66+0.3%4 of 5 stars2.75$54.13 9.0%8Gap Down1.48%MEDPMedpace$395.95+0.5%5 of 5 stars2.86$443.14 11.9%7Positive News1.27%PRGOPerrigo$26.24-2.3%5 of 5 stars3.00$39.67 51.2%3Positive News1.03%INCYIncyte$62.69+0.9%5 of 5 stars2.44$73.69 17.5%18Insider SellingShort Interest ↑High Trading Volume0.93%ALKSAlkermes$25.01+2.1%5 of 5 stars2.50$36.78 47.1%11Analyst ForecastShort Interest ↓Positive News0.93%ELANElanco Animal Health$18.23+1.1%2 of 5 stars2.57$18.29 0.3%7Positive News0.89%EXELExelixis$21.78+0.2%5 of 5 stars2.59$26.13 19.9%17Positive News0.85%NBIXNeurocrine Biosciences$135.29-0.1%5 of 5 stars2.80$152.00 12.4%25Positive News0.75%PBHPrestige Consumer Healthcare$64.86+0.9%4 of 5 stars2.50$91.25 40.7%40.57%MRUSMerus$55.77-1.4%3 of 5 stars3.00$73.60 32.0%12Analyst ForecastShort Interest ↑0.57%BPMCBlueprint Medicines$103.87-1.6%1 of 5 stars2.63$108.00 4.0%160.56%ILMNIllumina$109.07+0.4%5 of 5 stars2.29$158.14 45.0%21Analyst Forecast0.53%KRYSKrystal Biotech$177.710.0%4 of 5 stars3.00$177.63 0.0%9Positive News0.50%ITCIIntra-Cellular Therapies$68.87+1.6%5 of 5 stars2.91$91.50 32.9%11Analyst ForecastShort Interest ↓Positive News0.50%NUVLNuvalent$77.18-0.8%1 of 5 stars2.90$90.78 17.6%10Positive News0.48%ROIVRoivant Sciences$10.72+0.3%3 of 5 stars2.90$16.90 57.6%10Positive News0.48%BMRNBioMarin Pharmaceutical$85.02+1.8%5 of 5 stars2.57$106.11 24.8%21Short Interest ↓Positive News0.48%ACLXArcellx$53.75-1.2%2 of 5 stars3.07$78.00 45.1%14Insider SellingShort Interest ↑News Coverage0.47%RYTMRhythm Pharmaceuticals$41.16-3.8%3 of 5 stars2.83$54.33 32.0%6Positive News0.47%SRPTSarepta Therapeutics$116.83-4.9%5 of 5 stars2.80$164.00 40.4%15Analyst ForecastPositive News0.47%TGTXTG Therapeutics$16.57+0.1%4 of 5 stars2.83$29.83 80.0%6Positive News0.45%MLTXMoonLake Immunotherapeutics$40.17-3.0%1 of 5 stars2.75$74.46 85.4%120.45%IONSIonis Pharmaceuticals$40.76+0.3%4 of 5 stars2.67$58.43 43.3%15Analyst UpgradePositive News0.45%IDYAIDEAYA Biosciences$37.56-1.4%4 of 5 stars3.00$48.27 28.5%13Positive News0.41%RAREUltragenyx Pharmaceutical$39.80+1.9%4 of 5 stars2.93$86.71 117.9%14Analyst RevisionGap Down0.40%EXASExact Sciences$41.33-1.3%4 of 5 stars2.92$93.07 125.2%13Gap Up0.39%KYMRKymera Therapeutics$31.82-4.4%1 of 5 stars2.50$42.70 34.2%12Analyst ForecastInsider SellingPositive News0.37%VKTXViking Therapeutics$52.024 of 5 stars3.11$112.38 116.0%9Analyst Forecast0.36%CRSPCRISPR Therapeutics$61.79-2.8%1 of 5 stars2.31$73.46 18.9%17Analyst Forecast0.34%ACADACADIA Pharmaceuticals$14.84-0.5%4 of 5 stars2.75$28.94 95.0%160.31%ARVNArvinas$24.94-2.8%3 of 5 stars2.88$61.13 145.1%16Short Interest ↓Positive News0.31%BEAMBeam Therapeutics$24.03-3.4%1 of 5 stars2.38$40.18 67.2%13Short Interest ↓ This page (NASDAQ:FTXH) was last updated on 6/17/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredInflation Is Robbing You Blind! Here’s How to Fight Back!Quietly, inflation has reduced your purchasing power by 29.4% since 2014. So something that cost $100 in 20...American Alternative | SponsoredWho are Nvidia’s Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredHow Biden has already won 2024Obama’s Forever Term [Exposed] or Obama Biden has already won 2024 Exposed: the shocking election plot that...Porter & Company | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding First Trust Nasdaq Pharmaceuticals ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share First Trust Nasdaq Pharmaceuticals ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
